Will Fundamentals Overcome Growth Stock Downward Pressure?
Enovix has been steadily building momentum since their SPAC business combination and NASDAQ listing in mid 2021 however, the price action has recently reached a low, in-sync with the downward trend of other growth stocks as news that central banks would be increasing interest rates spreads uncertainty. Enovix's leadership team has laid out clear promises of commercial production and product revenue expectations in Q1 and Q2 2022. The price action may begin to take a turn upward and begin it's ascent back towards analysts predictions of $40.
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.